Parkinson’s Foundation expands free, at-home genetic testing initiative
By
Alicia Lasek (f3)
May 06, 2022
The organization is making an effort to connect a broader and more diverse set of candidates to clinical trials.
Clinical briefs for Wednesday, April 13
By
Alicia Lasek
Apr 13, 2022
Clinical trial partnerships could help assisted living change “long-term care” narrative … Number of nurse practitioners increases 9% since May … Experimental drug halves death rate in critically...
CMS restricts coverage of Alzheimer’s drug Aduhelm to clinical trials
By
Alicia Lasek
Apr 08, 2022
Coverage of aducanumab (Aduhelm) is officially limited to clinical trials only, the agency announced Thursday. Most stakeholders have called for restricted use while more efficacy and safety data is gathered,...
COVID-19 vaccine booster jab has 96 percent efficacy, Pfizer reveals
By
Alicia Lasek
Oct 22, 2021
A third dose of Pfizer-BioNTech’s vaccine restores protection against the disease to levels achieved after the second dose, a large new trial shows.
COVID-19 antiviral drug trials expected to wrap up within months: report
By
Alicia Lasek
Sep 27, 2021
Clinical trials for new COVID-19 antiviral drugs are expected to wrap up by winter, sparking hopes that a daily pill to treat COVID-19 infection is closer to fruition, according to a new report.
Pfizer, Merck start testing COVID prevention pills in late-stage trials
By
Alicia Lasek
Sep 02, 2021
The drugs, each given orally as a pill, would provide an unprecedented COVID-19 preventive medication option if brought to market.
New Alzheimer’s drug Aduhelm has no clinical benefit, panel of medical experts concludes
By
Alicia Lasek
Jul 21, 2021
The drug does not improve upon the current standard of care for Alzheimer’s disease, say advisers to the Institute for Clinical and Economic Review, a drug pricing watchdog.
AMDA: Don’t prescribe Aduhelm to long-term care residents without more testing
By
Alicia Lasek
Jul 01, 2021
“It is our responsibility to resist the urge to prescribe a potentially dangerous and ineffective medication that is untested in our population, even if it has FDA approval,” the LTC physician’s...
A first: Regeneron’s antibody cocktail cuts mortality by 20 percent in severe COVID
By
Alicia Lasek
Jun 17, 2021
The results are promising for vulnerable COVID-19 patients who can’t mount their own immune response to the disease, the study revealed. The findings also may ease uncertainty about the value of...
FDA approves first drug to slow Alzheimer’s in controversial decision
By
Alicia Lasek
Jun 07, 2021
The evidence convincingly shows that aducanumab (Aduhelm) removes beta amyloid — a hallmark of Alzheimer’s — from the brain, slowing the disease’s progression and giving patients and families much-needed...